0001104659-22-053625.txt : 20220429
0001104659-22-053625.hdr.sgml : 20220429
20220429162652
ACCESSION NUMBER: 0001104659-22-053625
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210805
FILED AS OF DATE: 20220429
DATE AS OF CHANGE: 20220429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klein Dov
CENTRAL INDEX KEY: 0001647971
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35366
FILM NUMBER: 22876029
MAIL ADDRESS:
STREET 1: C/O FORTRESS BIOTECH, INC.
STREET 2: 3 COLUMBUS CIRCLE, 15TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205157386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
FORMER COMPANY:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
4
1
tm2213913-10_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-08-05
0
0001429260
Fortress Biotech, Inc.
FBIO
0001647971
Klein Dov
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301
BAY HARBOR ISLAND
FL
33154
1
0
0
0
Common Stock, par value $0.001
2021-08-05
4
J
0
305
0
A
655305
D
Common Stock, par value $0.001
2021-09-30
4
J
0
480
0
A
655785
D
Common Stock, par value $0.001
2021-11-16
4
J
0
230
0
A
656015
D
Common Stock, par value $0.001
2021-12-28
4
S
0
5000
2.45
D
651015
D
Common Stock, par value $0.001
2022-01-01
4
A
0
100000
0
A
751015
D
The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.
The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock.
One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
The total holdings include 560,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.
/s/ Samuel Berry, Attorney-in-Fact
2022-04-29